MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, CTMX had -$14,856K decrease in cash & cash equivalents over the period. -$15,421K in free cash flow.

Cash Flow Overview

Change in Cash
-$14,856K
Free Cash flow
-$15,421K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-09-30
2025-06-30
Net income
-14,229 23,371
Amortization of intangible assets
36 73
Depreciation and amortization
98 659
Accretion of discounts on short-term investments
636 851
Stock-based compensation expense
1,384 3,439
Non-cash lease expense
-1,133 -2,189
Accounts receivable
-240 -1,234
Prepaid expenses and other assets
-708 1,076
Accounts payable
419 -853
Accrued liabilities and other long-term liabilities
-326 -3,209
Deferred revenue
-4,375 -61,772
Net cash used in operating activities
-15,548 -36,796
Purchases of property and equipment
-127 146
Purchases of short term investments
19,688 128,618
Maturities of short-term investments
20,000 83,000
Net cash (used in) provided by investing activities
439 -45,764
Proceeds from issuance of common stock, net of issuance costs
0 93,373
Proceeds from employee purchase plan and exercise of stock options
253 177
Net cash provided by financing activities
253 93,550
Net (decrease) increase in cash, cash equivalents and restricted cash
-14,856 10,990
Cash and cash equivalents at beginning of period
39,079 -
Cash and cash equivalents at end of period
35,213 -
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

CytomX Therapeutics, Inc. (CTMX)

CytomX Therapeutics, Inc. (CTMX)